Md Saiful Islam Khan
- The U.S. FDA on Thursday permitted Alnylam Prescription drugs’ (NASDAQ:ALNY) utility so as to add cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) to the labeling of its RNAi remedy Amvuttra (vutrisiran).
- The remedy was already permitted for polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN).